Health Encyclopedia

Nalbuphine

Nalbuphine: Essential Information, Dosage & Side Effects

Nalbuphine, a synthetic opioid, is an injectable medication used for the treatment of moderate to severe pain. Nalbuphine is a unique opioid analgesic that acts as both an agonist and an antagonist at different opioid receptors, providing pain relief while reducing the risk of respiratory depression and other adverse effects associated with traditional opioid analgesics.

History of Nalbuphine

Nalbuphine was first synthesized in the 1960s by researchers at Endo Laboratories (now Endo Pharmaceuticals) and was approved for medical use in the United States by the Food and Drug Administration (FDA) in 1979. It was developed as an alternative to traditional opioid analgesics with the goal of providing effective pain relief while minimizing the risk of respiratory depression and potential for abuse.

Source: Nalbuphine: drug for treatment of opioid-induced pruritus

Chemical Properties

Nalbuphine is a semi-synthetic opioid analgesic that is chemically related to the opioid antagonist naloxone. Its chemical structure differs from other opioid analgesics, as it contains a cyclobutane ring and a phenolic group. This unique structure contributes to its distinct pharmacological properties as an opioid agonist-antagonist.

Source: Nalbuphine” target=”_blank”> Nalbuphine – Compound Summary

Mechanism of Action

Nalbuphine is an opioid agonist-antagonist, meaning it exhibits both agonist (activating) and antagonist (blocking) properties at different opioid receptors. Specifically, nalbuphine acts as an agonist at the kappa opioid receptor and as an antagonist at the mu opioid receptor. This unique mechanism of action contributes to its analgesic effects while reducing the risk of respiratory depression and other adverse effects associated with traditional opioid analgesics.

Source: Nalbuphine

Pharmacology

Nalbuphine is administered intravenously, intramuscularly, or subcutaneously. It has a relatively rapid onset of action, with analgesia occurring within 2 to 3 minutes after intravenous administration and within 15 minutes after intramuscular or subcutaneous injection. The duration of action is typically 3 to 6 hours, depending on the dose and route of administration. Nalbuphine is metabolized in the liver and excreted primarily through the kidneys.

Source: Nalbuphine

Indications & Uses

The primary FDA-approved indications for nalbuphine include:

Off-label uses of nalbuphine may include treatment of opioid-induced pruritus (itching) and management of certain types of chronic pain.

Source: Nalbuphine Hydrochloride Injection

Administration

Nalbuphine is available as an injectable solution for intravenous, intramuscular, or subcutaneous administration. The recommended dosage for adults is 10 to 20 mg every 3 to 6 hours as needed for pain relief, with a maximum daily dose of 160 mg. Dosage adjustments may be necessary for patients with renal impairment or other specific conditions.

Source: Nalbuphine Dosing & Administration

Contraindications

Nalbuphine is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should also be avoided in patients with severe respiratory depression, acute or severe bronchial asthma, or paralytic ileus.

Source: Nalbuphine Hydrochloride Injection

Warnings and Precautions

Major warnings and precautions for nalbuphine include:

Patients should be monitored closely, and appropriate precautions should be taken during treatment with nalbuphine.

Source: Nalbuphine Hydrochloride Injection Label

Adverse Effects

Common adverse effects associated with nalbuphine include:

More serious adverse effects may include respiratory depression, sphincter of Oddi spasm, and potential for abuse and dependence.

Source: Nalbuphine Side Effects

Drug Interactions

Nalbuphine may interact with other central nervous system (CNS) depressants, such as alcohol, sedatives, hypnotics, and other opioid analgesics, potentially increasing the risk of respiratory depression and sedation. It may also interact with medications that affect hepatic or renal function, as these can alter the metabolism and excretion of nalbuphine.

Source: Nalbuphine Drug Interactions

Toxicity and Overdose

Symptoms of nalbuphine overdose may include respiratory depression, extreme drowsiness, and loss of consciousness. In case of overdose, supportive measures such as maintaining an open airway, providing assisted ventilation, and monitoring vital signs are recommended. Naloxone, an opioid antagonist, may also be administered to counteract the effects of nalbuphine overdose.

Source: Nalbuphine#section=Toxicity” target=”_blank”> Nalbuphine Toxicity Information

Patient Monitoring

During treatment with nalbuphine, patients should be monitored for:

Regular monitoring of vital signs, level of consciousness, and other relevant parameters is recommended.

Source: Nalbuphine Hydrochloride Injection Label

Use in Specific Populations

Pediatric use: Safety and efficacy of nalbuphine in children have not been established.

Use during pregnancy and labor: Nalbuphine crosses the placenta and may cause respiratory depression in the newborn. Use during pregnancy and labor should be carefully evaluated.

Geriatric use: Older patients may be more sensitive to the effects of nalbuphine, and dose adjustments may be necessary.

Source: Nalbuphine Hydrochloride Injection

Nalbuphine vs. Other Opioids

Unlike traditional opioid analgesics that act primarily as agonists at the mu opioid receptor, nalbuphine has a unique mechanism of action as an agonist-antagonist. This results in a lower risk of respiratory depression and a ceiling effect on analgesic activity, potentially reducing the risk of overdose. However, nalbuphine may be less potent than some other opioid analgesics in managing severe pain.

Source: Nalbuphine

In the United States, nalbuphine is classified as a Schedule II controlled substance by the Drug Enforcement Administration (DEA) due to its potential for abuse and dependence. It is subject to strict regulations and prescribing requirements to ensure proper use and minimize the risk of misuse or diversion.

Source: Controlled Substance Schedules

Brand Names and Availability

Nalbuphine is available under the brand name Nubain, which is manufactured by Endo Pharmaceuticals Inc. It is available in various strengths and formulations, including:

Nalbuphine may also be available as a generic product from various manufacturers.

Source: DailyMed: Nalbuphine Hydrochloride Injection

Clinical Studies and Research

Numerous clinical studies have been conducted to evaluate the efficacy, safety, and potential uses of nalbuphine. Some key areas of research include:

Ongoing research continues to explore the potential benefits and limitations of nalbuphine in various clinical scenarios.

Source: PubMed Search for “nalbuphine”

Patient Education

Patients should be educated about the proper use, potential side effects, and precautions associated with nalbuphine. Key points to discuss include:

Patients should also be advised to avoid activities that require mental alertness or coordination until they know how nalbuphine affects them.

Source: Nalbuphine Hydrochloride Injection

Historical and Future Perspectives

Nalbuphine was developed as an alternative to traditional opioid analgesics, aiming to provide effective pain relief while reducing the risk of respiratory depression and abuse potential. While it has been used for various indications, its unique mechanism of action and potential advantages continue to be explored in clinical research.

As the understanding of pain management and opioid receptor pharmacology evolves, nalbuphine may find expanded roles in specific clinical scenarios or as part of multimodal pain management strategies. However, its controlled substance status and potential for adverse effects also warrant careful consideration and monitoring.

Source: Nalbuphine: A Unique Opioid Analgesic with Some ”

Nalbuphine